When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a reasonable response. If the side effect is not dose-dependent (e.g., hypoglycemia with insulin), dose reduction does not address the issue.
Topic summary
What steady state means for the decision to escalate
This is a generated summary. It shows the 5 most-liked posts from a topic of 36, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
I read post #6 twice before replying, because I had assumed the opposite.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
28 likes 2mo
Worth separating two things that post #13 runs together.
Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of once-weekly dosing. The trade-off is convenience versus a slightly flatter concentration curve.
32 likes 1mo
MJayawardena, post #25: Micro-titration: the concept of increments smaller than the labelled steps. It has no evidence base from trials but is described by some people. The downside is that very small increments are hard to measure accurately with a syringe. Go to post
Worth separating two things that post #24 runs together.
Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.
r.coelho, post #28: Worth separating two things that post #24 runs together. Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense. Go to post
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Read the full topic (36 posts)
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: Why "dose equivalence" between different incretin analogues is a weak concept
Asking directly, because I could not find a straight answer: Why "dose equivalence" between different incretin analogues is a weak concept Reporting something rather than asking about it, in case the pattern…
|
+7 | 11 | 26k | 9mo |
|
Stepping down deliberately, and how to do it without losing progress
Stepping down deliberately, and how to do it without losing progress — setting out what I have, and where I think it stops being reliable. Practical question with the units stated, because I have seen how…
|
+98 | 102 | 26k | 3mo |
|
How the published trials escalated, tabulated side by side — does this still hold?
Asking directly, because I could not find a straight answer: How the published trials escalated, tabulated side by side — does this still hold? A question about technique rather than about dose. I have been…
|
2 | 8.9k | 9mo | |
|
Coming back to: Where the four-week escalation interval comes from, and what it is not
Posting this under the heading it deserves: Where the four-week escalation interval comes from, and what it is not Everything below is what sits behind that. I have read the maintained page on this and I…
|
+44 | 48 | 11k | 1d |
|
Reaching a dose and staying there for a year: a longitudinal note
Reaching a dose and staying there for a year: a longitudinal note Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still have a…
|
2 | 763 | 15mo |
Related topics — sharing the tags semaglutide, titration, tirzepatide
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] What steady state means for the decision to escalate
The question in the title: What steady state means for the decision to escalate I will give what I have already checked below so nobody repeats it. I have read the maintained page on this and I still have a…
|
+127 | 137 | 32k | 8mo |
|
Albumin binding and how it produces a long half-life
Albumin binding and how it produces a long half-life — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I repeat it anywhere. A…
|
+38 | 44 | 6.6k | 14mo |
|
Cold solution and stinging: the simplest fix
Posting this under the heading it deserves: Cold solution and stinging: the simplest fix Everything below is what sits behind that. Reporting something rather than asking about it, in case the pattern is…
|
+35 | 39 | 8.2k | 30d |
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…
|
+52 | 57 | 25k | just now |
|
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold?
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N…
|
+58 | 62 | 49k | 20mo |